ABSTRACT -In a retrospective audit data were collected on all 231 patients from 26 hospitals diagnosed with AML in the south and west region of the UK in 1996. Their median age at diagnosis was 67 years. Sixty one percent (142/231) of patients were treated with chemotherapy; most of the rest received blood product support only; and 7% (15) had no treatment at all. Sixty eight percent of patients aged under 60 years were treated in a clinical trial compared with 24% of patients over 60. The major reasons given for not entering patients in a trial were ineligibility in the younger cohort and poor performance status in the older group. Twenty elderly patients (12.5%) refused to be entered in a trial.
The annual incidence of acute myeloid leukaemia (AML) is approximately 2.4 per 100,000 1 , increasing progressively with age to a peak of 12.6 per 100,000 in adults 65 years of age or older. The outcome for patients with AML has improved substantially over the last three decades as a consequence of progress achieved by clinical trials, which have introduced changes in chemotherapeutic drugs and developed dose intensification with bone marrow transplantation. The headline survival figures quoted for such treatments are only applicable to young fit individuals who form the minority of patients, while AML is predominantly a disease of the elderly. There is a clear linear decrease in the percentage of patients achieving a complete remission of leukaemia as age increases, from 70% in adults under 50 years of age to 22% in patients over 75 years 2 . Age is an important prognostic factor in virtually all large co-operative group studies [3] [4] [5] [6] due to a number of factors, including an increasing incidence of secondary leukaemias 7 , cytogenetic abnormalities 8 , resistance of leukaemic cells to cytotoxic drugs 9 and significant co-morbidity.
The standard treatment for these older patients is not clear. Three strategies are commonly employed: standard chemotherapy, attenuated dose chemotherapy or palliative treatment with blood product support only. Although treatment with chemotherapy in this age group achieves better survival than no treatment 10, 11 , these trials again involve highly selected patients, and clinical trials in elderly patients have failed to show the improvement in outcome clearly seen in the younger patients.
This audit was undertaken in the south-west of the United Kingdom to examine all patients diagnosed with AML in the calendar year 1996. Our aim was to examine diagnostic and treatment approaches in this unselected population-based cohort with a particular focus on clinical trial participation.
Method
The south and west Regional Cancer Organisation (RCO) tumour panel in haematological oncology designed a simple single page proforma for data collection. The cohort of patients comprised all newly diagnosed cases of AML presenting during 1996 at each participating centre. All consultant haematologists at 26 acute hospital trusts in the south and west region agreed to take part in the study.
Patient details were collected by the clinical team and completed forms were sent to the RCO office. Data were collected from June 1997 to May 1998 by the central data management team at the RCO office.
Care was taken to exclude patients who may have been entered twice as a result of moving between hospitals within the region during therapy.
Results

Patient characteristics
Data were collected on 231 patients. One small trust did not have any cases of AML to report for 1996. The age distribution of the cohort is illustrated in Fig 1. The median age is 67 years and there is a slight male predominance (51%).
One hundred and thirty three patients (58%) were diagnosed as primary de novo AML and 87 patients (38%) were identified as secondary AML; in 11 cases no classification was given. The median age of the primary AML group was 65 years (range 1-89) and the median age of the secondary AML group was 73 years (range . Most of the patients with secondary leukaemia evolved from a prior myelodysplastic state but eight patients over 60 years (5%) and four patients under 60 years (6%) had an earlier history of exposure to chemotherapy or radiotherapy.
Management
Chemotherapy was administered to 142 patients (61%) with a median age of 62 years (range 1-92). Chemotherapy was administered to 71% of patients with primary de novo AML and 51% of patients with secondary AML. Eighty eight patients (40%), median age 78 (range 17-95), received no chemotherapy; no data were available for one patient. Most of these patients received palliative treatment with blood products only; 15 of them (7%) (median age 78, range 36-95) received no treatment at all either because they refused or died before appropriate therapy could be administered. One young patient who refused all therapy was a Jehovah's Witness.
In 26 patients high dose therapy and autologous or allogeneic bone marrow transplantation was identified as a component of the initial treatment strategy.
Clinical trial involvement
The involvement of patients in clinical trials by age is shown in Fig 2. No data were available on two patients. Sixty eight percent (47/68) of patients aged less than 60 years were treated in the context of a clinical trial of AML treatment. Of this group of 68 patients (data available on 67 patients) 79% (42/53) with primary de novo AML entered a clinical trial compared with 36% (5/14) of patients with secondary AML. The main reasons recorded for treatment outside a clinical trial of AML therapy were ineligibility (eight cases), lack of local infrastructure to conduct clinical trials (four cases, one centre), patient refusal to participate (two cases) and poor general fitness (two cases). In six cases no information was provided.
In contrast, only 24% (38/161) of patients over 60 years received chemotherapy in the context of a clinical trial. This represents 45% (38/81) of patients in this age range who received any form of chemotherapy. The majority of those treated were aged less than 70 and were entered into the Medical Research Council 11 trial for elderly patients with AML. Patients not entered were medically unfit or had a specific contra-indication to treatment, while 12.5% (20/161) refused trial entry.
Outcome
Complete remission was documented in 54% of patients aged less than 60. Of these patients 84% treated within a clinical trial achieved complete remission. The remission rate was higher in patients with primary de novo AML than in secondary AML (72% and 17% respectively). Twenty three patients under 60 are known to have died (34%), mostly as a consequence of leukaemia. Complete remission was achieved in 32 patients aged over 60 (20%). For patients treated within a clinical trial the complete remission rate is 44%. One hundred and fourteen patients aged 60 years and older are known to have died (69%), and although the majority died of leukaemia, 31 (27%) died as a result of complications of treatment.
Discussion
This is a retrospective study of the incidence, management and outcome of all patients diagnosed with acute leukaemia in the south and west of the United Kingdom over a period of one year. AML is uniformly well diagnosed: in the Medical Research Council AML10 study only 18 of 1966 patients from 163 institutions, throughout the UK and abroad, were excluded owing to mistaken diagnosis 12 . This study represents all patients diagnosed for a population of 6.5 million and demonstrates an annual incidence of 3.5/100,000.
Accepting the limitations of such a study, some clear trends are seen. AML is a disease of the elderly. In this study the median age at presentation was 67 years, which is slightly older than in other studies 13, 14 . Many elderly patients have secondary leukaemia arising from an earlier myelodysplastic state but in this unselected cohort only 6% of patients under 60 and 5% over 60 had a previous history of exposure to chemotherapy or radio- therapy, a rate lower than expected 15 . In the majority of cases and in all hospitals advanced diagnostic techniques are applied. Only in the very elderly are they not used, reflecting the fact that such information is often not relevant to the management of such patients.
Headline treatments such as high dose therapy with autologous or allogeneic bone marrow transplantation 16 , although resource intensive, are only relevant to a minority of patients presenting with this illness.
Information on outcome is limited and no real conclusions can be drawn. It may be inferred that patients entered on trials have a better outcome, but this may simply reflect patient selection.
The accrual of patients under 60 into clinical trials is impressively high. Across a totally unselected population this represents almost 70% of patients. This demonstrates a genuine commitment from clinicians, as a result of which the outcome for these patients has improved significantly over the last three decades. The outcome for elderly patients with AML has not kept pace with that of younger patients, but it is clear that these patients do better if treated with chemotherapy, prompting suggestions that all elderly patients should receive full dose chemotherapy 11 . This advice is based on published studies of highly selected patients and in some cases emanates from referral centres that fail to see the true spectrum of patients reported here. There is clearly a subset of elderly patients who are amenable to treatment; they have received therapy and some have been entered into studies. Why has the majority of older patients not been enrolled in trials? For trials to recruit successfully, two factors are needed. First, a commitment on the part of the clinician to the process which includes having the necessary infrastructure; second, studies that are applicable and acceptable to both doctor and patient. The same haematologists who enthusiastically enrol young patients into studies fail to enter the elderly. This suggests that trials in this age group must be reexamined. Perhaps trials for this group of patients should aim primarily to examine quality of life issues rather than to attain complete remission with increasingly complicated and intensive chemotherapy.
This has broader implications. At a time when we are starting to define acceptable standards of care for cancer it is important that these are based not on published -and therefore, by definition, selected -patients but on population based standards. In a population based study from Toronto overall the complete remission rate of all patients diagnosed with AML was 43.8% 17 . However, when the usual exclusions were applied this rose to 85.3%. It is clear from this study and our own that the results from clinical trials only apply to a minority of patients, yet if the percentage of patients entered into trials is to be defined as a quality standard, then it is important for those trials to be relevant to the population that is being treated. 
